Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
Rhea-AI Summary
Tiziana Life Sciences (Nasdaq: TLSA) announced on Dec 15, 2025 that it has withdrawn its proposed public offering of common shares. The company said the withdrawal was made due to market conditions. The release also states that it does not constitute an offer to sell or a solicitation to buy securities in any jurisdiction prior to required registration or qualification.
Positive
- None.
Negative
- Proposed public offering of common shares withdrawn on Dec 15, 2025
- Withdrawal attributed to market conditions, pausing planned equity financing
News Market Reaction – TLSA
In the Dec 15 session, TLSA declined 10.67%, reflecting a significant negative market reaction. Argus tracked a peak move of +17.7% during that session. Argus tracked a trough of -20.7% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 5.6x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | Clinical trial update | Positive | +3.5% | Phase 2 Alzheimer’s trial enrollment and first dosing timeline for foralumab. |
| Dec 02 | Strategic transaction | Positive | +0.0% | Planned spinout of IL-6 asset TZLS-501 into a separate listed company. |
| Nov 25 | Clinical trial update | Positive | +5.2% | ALS Phase 2 foralumab trial accepted into Healey ALS MyMatch Program. |
| Nov 13 | Conference presentation | Positive | -7.3% | Jefferies conference presentation highlighting pipeline and clinical milestones. |
| Oct 29 | Conference presentation | Positive | -3.1% | BIO-Europe 2025 participation focused on intranasal foralumab and nasal platform. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and pipeline updates often saw aligned or modestly positive price reactions, while conference-related news occasionally coincided with negative moves.
Over the last few months, Tiziana reported several pipeline milestones centered on intranasal foralumab. On Nov 25, its ALS Phase 2 trial entered the Healey ALS MyMatch Program, and on Dec 12 it prepared to dose the first patient in a Phase 2 Alzheimer’s trial, both with positive price reactions. Strategic plans to spin out the IL-6 asset announced on Dec 2 saw little immediate move, while conference presentations on Nov 13 and Oct 29 coincided with negative trading days.
Key Terms
intranasal foralumab medical
anti-CD3 monoclonal antibody medical
public offering financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the withdrawal of the proposed public offering of common shares due to market conditions.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
